Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 281

1.

Systematic review of combination drug therapy for non-neurogenic male lower urinary tract symptoms.

Füllhase C, Chapple C, Cornu JN, De Nunzio C, Gratzke C, Kaplan SA, Marberger M, Montorsi F, Novara G, Oelke M, Porst H, Roehrborn C, Stief C, McVary KT.

Eur Urol. 2013 Aug;64(2):228-43. doi: 10.1016/j.eururo.2013.01.018. Epub 2013 Jan 25. Review.

PMID:
23375241
2.

Current medical treatment of lower urinary tract symptoms/BPH: do we have a standard?

Silva J, Silva CM, Cruz F.

Curr Opin Urol. 2014 Jan;24(1):21-8. doi: 10.1097/MOU.0000000000000007. Review.

PMID:
24231531
3.

EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction.

Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, Michel MC, N'dow J, Nordling J, de la Rosette JJ; European Association of Urology.

Eur Urol. 2013 Jul;64(1):118-40. doi: 10.1016/j.eururo.2013.03.004. Epub 2013 Mar 13. Review.

PMID:
23541338
4.

[Combination therapy of benign prostate syndrome/lower urinary tract symptoms].

Madersbacher S.

Urologe A. 2013 Feb;52(2):212-8. doi: 10.1007/s00120-012-3055-7. Review. German.

PMID:
23340696
5.

A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.

Gacci M, Corona G, Salvi M, Vignozzi L, McVary KT, Kaplan SA, Roehrborn CG, Serni S, Mirone V, Carini M, Maggi M.

Eur Urol. 2012 May;61(5):994-1003. doi: 10.1016/j.eururo.2012.02.033. Epub 2012 Feb 25. Review.

PMID:
22405510
6.

Medical management of lower urinary tract symptoms in men with benign prostatic enlargement.

Marberger M.

Adv Ther. 2013 Apr;30(4):309-19. doi: 10.1007/s12325-013-0022-7. Epub 2013 Apr 12. Review.

PMID:
23584673
7.

Management of lower urinary tract symptoms related to benign prostatic hyperplasia in real-life practice in france: a comprehensive population study.

Lukacs B, Cornu JN, Aout M, Tessier N, Hodée C, Haab F, Cussenot O, Merlière Y, Moysan V, Vicaut E.

Eur Urol. 2013 Sep;64(3):493-501. doi: 10.1016/j.eururo.2013.02.026. Epub 2013 Feb 26.

PMID:
23465519
8.

Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia.

Gacci M, Eardley I, Giuliano F, Hatzichristou D, Kaplan SA, Maggi M, McVary KT, Mirone V, Porst H, Roehrborn CG.

Eur Urol. 2011 Oct;60(4):809-25. doi: 10.1016/j.eururo.2011.06.037. Epub 2011 Jun 29. Review.

PMID:
21726934
9.

Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension.

Drake MJ, Chapple C, Sokol R, Oelke M, Traudtner K, Klaver M, Drogendijk T, Van Kerrebroeck P; NEPTUNE Study Group.

Eur Urol. 2015 Feb;67(2):262-70. doi: 10.1016/j.eururo.2014.07.013. Epub 2014 Jul 25.

PMID:
25070148
10.

Combination therapy for non-neurogenic male lower urinary tract symptoms: 1 + 1 does not equal 2.

Lepor H.

Eur Urol. 2013 Aug;64(2):244-6; discussion 246-7. doi: 10.1016/j.eururo.2013.02.021. Epub 2013 Feb 19. No abstract available.

PMID:
23473577
11.

[Initial assessment, follow-up and treatment of lower urinary tract symptoms related to benign prostatic hyperplasia: guidelines of the LUTS committee of the French Urological Association].

Descazeaud A, Robert G, Delongchamps NB, Cornu JN, Saussine C, Haillot O, Devonec M, Fourmarier M, Ballereau C, Lukacs B, Dumonceau O, Azzouzi AR, Faix A, Desgrandchamps F, de la Taille A; Comité des troubles mictionnels de l’homme de l’association française d’urologie.

Prog Urol. 2012 Dec;22(16):977-88. doi: 10.1016/j.purol.2012.10.001. Epub 2012 Nov 6. French.

PMID:
23178093
12.

The use of pharmacotherapy for male patients with urgency and stress incontinence.

Andersson KE.

Curr Opin Urol. 2014 Nov;24(6):571-7. doi: 10.1097/MOU.0000000000000106. Review.

PMID:
25144147
13.

Antimuscarinics for treatment of storage lower urinary tract symptoms in men: a systematic review.

Kaplan SA, Roehrborn CG, Abrams P, Chapple CR, Bavendam T, Guan Z.

Int J Clin Pract. 2011 Apr;65(4):487-507. doi: 10.1111/j.1742-1241.2010.02611.x. Epub 2011 Jan 7. Review.

PMID:
21210910
14.

Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial.

Kaplan SA, He W, Koltun WD, Cummings J, Schneider T, Fakhoury A.

Eur Urol. 2013 Jan;63(1):158-65. doi: 10.1016/j.eururo.2012.07.003. Epub 2012 Jul 17.

PMID:
22831853
15.

The role of combination medical therapy in benign prostatic hyperplasia.

Greco KA, McVary KT.

Int J Impot Res. 2008 Dec;20 Suppl 3:S33-43. doi: 10.1038/ijir.2008.51. Review.

PMID:
19002123
16.
17.

BPH/LUTS and ED: common pharmacological pathways for a common treatment.

Fusco F, D'Anzeo G, Sessa A, Pace G, Rossi A, Capece M, d'Emmanuele di Villa Bianca R.

J Sex Med. 2013 Oct;10(10):2382-93. doi: 10.1111/jsm.12261. Epub 2013 Jul 22. Review.

PMID:
23875757
18.

Latest treatment for lower urinary tract dysfunction: therapeutic agents and mechanism of action.

Yamaguchi O.

Int J Urol. 2013 Jan;20(1):28-39. doi: 10.1111/iju.12008. Epub 2012 Nov 28. Review.

19.

Comparative effectiveness of oral drug therapies for lower urinary tract symptoms due to benign prostatic hyperplasia: a systematic review and network meta-analysis.

Wang X, Wang X, Li S, Meng Z, Liu T, Zhang X.

PLoS One. 2014 Sep 12;9(9):e107593. doi: 10.1371/journal.pone.0107593. eCollection 2014.

20.

Silodosin in the management of lower urinary tract symptoms as a result of benign prostatic hyperplasia: who are the best candidates.

Capitanio U, Salonia A, Briganti A, Montorsi F.

Int J Clin Pract. 2013 Jun;67(6):544-51. doi: 10.1111/ijcp.12135. Epub 2013 Feb 15. Review.

PMID:
23409749

Supplemental Content

Support Center